Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

431988

	registered interest
	date	24/11/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the (a) reduction in cases of and deaths from human pappillomavirus (HPV) as a result of the introduction of the HPV vaccine to the UK schedule in 2008, (b) number of HPV vaccinations administered in each year since that programme began and (c) cost of delivering that programme in each year since 2008.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	17428
	answer	answer is ministerial correction date of answer 02/12/2015 answer text <p>HPV vaccination will eventually prevent hundreds of deaths due to cervical cancer every year. Public Health England (PHE) expect the major benefit of the vaccination programme, i.e. a decrease in cervical cancer, which peaks in women between 25 and 50; will be seen in some years’ time.</p><br /><p>Table 1: Number of HPV vaccine doses given for the academic years 2008/09 to 2013/14.</p><table><tbody><tr><td><p>Academic Year</p></td><td><p>Total doses given</p></td></tr><tr><td><p>2008/09 -2010/11<sup>1</sup> (routine and catch-up cohorts*)</p></td><td><p>5,319,058<sup>$</sup></p></td></tr><tr><td><p>2011/12<sup>2</sup> (routine only) <br></p></td><td><p>784,831</p></td></tr><tr><td><p>2012/13<sup>3</sup> (routine only) <br></p></td><td><p>766,832</p></td></tr><tr><td><p>2013/14<sup>4</sup> (routine only) <br></p></td><td><p>762,038</p></td></tr><tr><td><p>2014/15 (routine only) <br></p></td><td><p>Not available</p></td></tr></tbody></table><br /><p>*Routine cohort are school Yr8 females (aged 12-13 years) in academic years 2008/09, 2009/10, 2010/11) and catch-up cohorts are females born between 1/9/1990 and 31/8/1995. <sup>$</sup> Data for 2008/09, 2009/10 and 2010/11 are combined as these years had both routine and catch-up cohorts targeted and include some ‘mop-up’ vaccinations for eligible females receiving vaccine(s) after the academic year they first became eligible for vaccination.</p><br /> <br /><p>Table 2. The cost of delivering the HPV programme since 2008.</p><table><tbody><tr><td><p>Financial year</p></td><td><p>Estimated total programme costs</p></td></tr><tr><td><p>2008/09</p></td><td><p>£51 million</p></td></tr><tr><td><p>2009/10</p></td><td><p>£114 million (includes catch up campaign)</p></td></tr><tr><td><p>2010/11</p></td><td><p>£40 million</p></td></tr><tr><td><p>2011/12</p></td><td><p>£27 million (change in dosage schedule)</p></td></tr><tr><td><p>2012/13</p></td><td><p>£24 million</p></td></tr><tr><td><p>2013/14</p></td><td><p>£28.2 million</p></td></tr><tr><td><p>2014/15</p></td><td><p>£16.3 million (change from 3 to 2 doses)</p></td></tr></tbody></table><p><em></em></p><p>These are the estimated full programme costs (including the cost of the vaccine) for England, inclusive of VAT.</p><br /><p><strong></strong></p><p><strong><br> </strong></p><p><strong></strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/12/2015 18:04:42 answering member 3918 label Biography information for Jane Ellison
	tabling member	1506 label Biography information for Andrew Gwynne

521263

	registered interest
	date	24/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether his Department holds information on the number of boys receiving HPV vaccinations through private provision.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	38128
	answer	answer is ministerial correction date of answer 02/06/2016 answer text <p>The Department does not hold information on the number of boys receiving human papillomavirus vaccinations through private provision.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/06/2016 15:39:45 answering member 3918 label Biography information for Jane Ellison
	tabling member	1506 label Biography information for Andrew Gwynne

521269

	registered interest
	date	24/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he plans to publish the equality impact assessment on the proposed HPV vaccination programme for men who have sex with men.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	38131
	answer	answer is ministerial correction date of answer 02/06/2016 answer text <p>Public Health England is starting a human papillomavirus (HPV) vaccination pilot for men who have sex with men in June 2016. Information gathered during the pilot will help inform an equality impact assessment for a national programme if the pilot is successful.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/06/2016 15:36:56 answering member 3918 label Biography information for Jane Ellison
	tabling member	1506 label Biography information for Andrew Gwynne

521589

	registered interest
	date	25/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will request that the Joint Committee on Vaccination and Immunisation undertakes an assessment of the recommendation from the Britain Against Cancer conference held in December 2015 to report its review on extending HPV vaccination to boys in 2016.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	38503
	answer	answer is ministerial correction date of answer 10/06/2016 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) advice needs to be based on a robust cost-effectiveness analysis. This is underway and Public Health England is due to report by early 2017. The JCVI has agreed that shortcuts could undermine the validity of the results and will begin its deliberations on extending vaccination to adolescent boys once all the necessary evidence is available. It is important that we follow a proper process and that the JCVI has a full understanding of the cost-effectiveness of vaccination programmes.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2016 10:54:05 answering member 3918 label Biography information for Jane Ellison
	tabling member	1506 label Biography information for Andrew Gwynne

522126

	registered interest
	date	26/05/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	38833
	answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>There are <del class="ministerial">two</del> <ins class="ministerial">three </ins>human papilloma virus vaccines licensed in the European Union: Cervarix<ins class="ministerial">,</ins> <del class="ministerial">and</del> <ins class="ministerial">Gardasil and </ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.</p><p> </p><p>Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:</p><p> </p><p><a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">https://www.clinicaltrialsregister.eu/ctr-search/search</a></p><p> </p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 10:57:37 question first ministerially corrected 13/06/2016 10:14:27 answering member 4020 label Biography information for George Freeman previous answer version 2228 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

421117

	registered interest
	date	13/10/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of the implications for its policy of the potential link between the HPV Vaccine and Postural Orthostatic Tachycardia Syndrome; and what assessment he has made of the effect of such a link on the progress of the Government's HPV vaccination programme.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	uin	11694
	answer	answer is ministerial correction date of answer 21/10/2015 answer text <p>The human papillomavirus (HPV) sub-committee of the Joint Committee on Vaccination and Immunisation (JCVI), which advises the Department on immunisation matters, considered the safety of HPV vaccine when it met in June 2015. The sub-committee reviewed safety information provided by the Medicines and Healthcare products Regulatory Agency (MHRA), as well as reports in the media and literature investigating temporal associations of the HPV vaccine to a range of overlapping syndromes including postural orthostatic tachycardia syndrome (POTS). The HPV sub-committee agreed that no available evidence supports a causative link between HPV vaccination and POTS or other overlapping syndromes. It strongly supported the continued use of the HPV vaccine to prevent infection with HPV and to protect adolescent girls from cervical and other HPV associated cancers. This position was agreed by the JCVI, which concluded it has no concerns about the safety of the HPV vaccine.</p><br /><p>As with all vaccines and medicines, the safety ofHPV vaccines will be kept under continual review.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 21/10/2015 16:21:45 answering member 3918 label Biography information for Jane Ellison
	tabling member	1447 label Biography information for Andrew Rosindell

1233372

	registered interest
	date	10/09/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the covid-19 outbreak does not adversely affect HPV vaccination uptake rates across the UK.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	88281
	answer	answer is ministerial correction date of answer 09/10/2020 answer text <p>School-aged vaccinations, including human papillomavirus (HPV), were impacted by the closure of schools during the COVID-19 pandemic. School-aged immunisation providers across the country are now working with NHS England and NHS Improvement commissioners with clinical advice from Public Health England to catch up those vaccinations that were previously paused. From July, over 90% of all school aged providers across England have re-established services and are currently delivering catch-up programmes to those that missed vaccinations.</p><p>The priority for all NHS England and NHS Improvement commissioned school-aged immunisation providers is to ensure all those eligible are offered at least one dose of HPV vaccine by the end of the next academic year, based on the Joint Committee on Vaccination and Immunisation recommendation.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/10/2020 14:46:55 answering member 4380 label Biography information for Jo Churchill
	tabling member	3930 label Biography information for Caroline Lucas

642297

	registered interest
	date	22/11/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when the Joint Committee on Vaccination and Immunisation is expected to make a recommendation on the issuing of HPV vaccination for adolescent boys.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	54217
	answer	answer is ministerial correction date of answer 30/11/2016 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), advises Ministers on immunisation related issues, is currently in the process of considering the impact and cost-effectiveness of extending the human papillomavirus (HPV) vaccination to adolescent boys.</p><p> </p><p>The JCVI will need to consider mathematical modelling by Public Health England (PHE) on the impact and cost effectiveness of extending the HPV vaccination to adolescent boys, ahead of developing its advice. PHE is expected to report its modelling assessment to the Committee in early 2017.</p><p> </p><p>The JCVI will consider the analysis from PHE at the earliest opportunity. Once the Committee is satisfied it has reviewed all the necessary evidence it will then be expected to make its advice.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 30/11/2016 17:59:22 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3930 label Biography information for Caroline Lucas

642300

	registered interest
	date	22/11/2016
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether the Joint Committee on Vaccination and Immunisation's assessment of the cost-effectiveness of HPV vaccination for boys includes the (a) social care, (b) social security and (c) other costs of HPV-related diseases that are not borne directly by the NHS; and if he will make a statement.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	54234
	answer	answer is ministerial correction date of answer 30/11/2016 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) follows standard guidelines from the National Institute for Health and Care Excellence on mathematical modelling and cost-effectiveness. This means that the JCVI takes into account the costs and benefits of a programme from a health perspective to ensure that the best possible health outcomes are delivered from the health, and where relevant, social care budgets.</p><p> </p><p>The JCVI expects to receive a report from Public Health England in early 2017 on the impact and cost effectiveness of extending the human papillomavirus vaccination to adolescent boys. As part of its considerations the JCVI will review whether all appropriate costs and benefits have been taken into account.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 30/11/2016 17:58:44 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3930 label Biography information for Caroline Lucas

784910

	registered interest
	date	06/11/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Human Papillomavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he plans to publish the evaluation of the HPV vaccination pilot for men who have sex with men.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	111700
	answer	answer is ministerial correction date of answer 13/11/2017 answer text <p>The evaluation of the human papilloma virus vaccination pilot for men who have sex with men will be published in the near future.</p><p> </p><p>It will be published on the GOV.UK website at:</p><p> </p><p><a href="https://www.gov.uk/government/publications/hpv-vaccination-pilot-for-men-who-have-sex-with-men-msm" target="_blank">https://www.gov.uk/government/publications/hpv-vaccination-pilot-for-men-who-have-sex-with-men-msm</a></p><p><strong> </strong></p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/11/2017 16:50:11 answering member 4067 label Biography information for Steve Brine
	tabling member	3930 label Biography information for Caroline Lucas